Financial Statements, Audit Reports and Supplementary Information in Accordance With the Uniform Guidance For the Year Ended September 30, 2024 (With Summarized Information for 2023) With Independent Auditor's Reports



FUND FOR PUBLIC HEALTH IN NEW YORK, INC. Financial Statements and Additional Information Year Ended September 30, 2024

TABLE OF CONTENTS

	Page(s)
INDEPENDENT AUDITOR'S REPORT	1–3
FINANCIAL STATEMENTS	
Statements of Financial Position	4–5
Statement of Operations and Changes in Net Assets	6
Statement of Functional Expenses	7
Statements of Cash Flows	8
Notes to Financial Statements	9–25
SUPPLEMENTARY INFORMATION AND INDEPENDENT AUDITOR'S REPORTS	
Schedule of Expenditures of Federal Awards	26–32
Notes to Schedule of Expenditures of Federal Awards	33–36
Independent Auditor's Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of the Financial Statements Performed in Accordance with Government Auditing Standards	37–38
Independent Auditor's Report on Compliance for Each Major Federal Program and Report on Internal Control over Compliance in Accordance with the Uniform Guidance	39–41
Schedule of Findings and Questioned Costs	42–44
Summary Schedule of Prior-Year Audit Findings	45



INDEPENDENT AUDITOR'S REPORT

To Management and the Board of Directors Fund for Public Health in New York, Inc.

Report on the Financial Statements

Opinion

We have audited the accompanying financial statements of Fund for Public Health in New York, Inc. (the Organization), which comprise the statements of financial position as of September 30, 2024, the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of Fund for Public Health in New York, Inc. as of September 30, 2024, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Organization, and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for one year after the date that the financial statements are issued or are available to be issued.

80 Pine Street New York, NY 10005 **T** +1 212 709 4500 **F** +1 212 709 4680



Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and Government Auditing Standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether
 due to fraud or error, and design and perform audit procedures responsive to those risks.
 Such procedures include examining, on a test basis, evidence regarding the amounts and
 disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit
 procedures that are appropriate in the circumstances, but not for the purpose of expressing
 an opinion on the effectiveness of the Organization's internal control. Accordingly, no such
 opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying schedule of expenditures of federal awards (the Schedule) is presented for purposes of additional analysis as required by the audit requirements of Title 2 U.S. Code of Federal Regulations (CFR) Part 200, Uniform Administrative Requirements, Cost



Principles, and Audit Requirements for Federal Awards (the Uniform Guidance), and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the Schedule is fairly stated in all material respects in relation to the financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we also have issued our report dated June 30, 2025 on our consideration of the Organization's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Organization's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Organization's internal control over financial reporting and compliance.

Report on Summarized Comparative Information

Mitchell: Titus. LLP

We have previously audited the Organization's September 30, 2023 financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated June 28, 2024. In our opinion, the summarized comparative information presented herein as of and for the year ended September 30, 2023 is consistent, in all material respects, with the audited financial statements from which it has been derived.

June 30, 2025

Statements of Financial Position As of September 30, 2024 and 2023

	2024	2023		
ASSETS				
Current assets				
Cash and cash equivalents	\$ 19,227,903	\$ 13,288,090		
Investments	10,373,483	-		
Grants and contributions receivable, net	44,986,396	82,262,615		
Prepaid expenses	59,030	51,359		
Total current assets	74,646,812	95,602,064		
Other assets				
Property and equipment, net of accumulated				
depreciation (\$579,293 in 2024 and \$496,449				
in 2023)	217,629	300,473		
ROU lease asset operating	1,506,114	2,053,791		
Contract advance	433,054	1,915,846		
Beneficial interest in assets held by others	1,010,578	960,121		
Other assets		79,274		
Total other assets	3,167,375	5,309,505		
Total assets	\$ 77,814,187	\$ 100,911,569		

Statements of Financial Position *(continued)* As of September 30, 2024 and 2023

	2024	2023		
LIABILITIES AND NET ASSETS Current liabilities				
Accounts payable and accrued expenses	\$ 17,306,218	\$ 36,037,111		
Accrued payroll and benefits	3,740,792	3,244,718		
Other liabilities	22,895,885	14,622,477		
Total current liabilities	43,942,895	53,904,306		
Other liabilities				
Endowment advance	867,547	867,547		
ROU lease liability operating	1,629,229	2,116,945		
Total other liabilities	2,496,776	2,984,492		
Total liabilities	46,439,671	56,888,798		
Net assets				
Without donor restrictions	2,823,031	13,665,600		
With donor restrictions	28,551,485	30,357,171		
Total net assets	31,374,516	44,022,771		
Total liabilities and net assets	\$ 77,814,187	\$ 100,911,569		

Statement of Operations and Changes in Net Assets For the Year Ended September 30, 2024 (With Summarized Financial Information for 2023)

		2024		2023
	Without	With		
	Donor	Donor		
	Restrictions	Restrictions	Total	Total
REVENUE AND RECLASSIFICATIONS Direct support from federal				
government	\$ 11,566,102	\$ -	\$ 11,566,102	\$ 30,714,070
Pass-through grants from federal	, , ,		. , ,	, , ,
government	66,916,695	-	66,916,695	67,138,346
Contributed nonfinancial assets	2,537,358	-	2,537,358	4,137,254
Other grants and contributions	9,456,984	7,988,547	17,445,531	25,578,352
Other	447,097	-	447,097	434,952
Net assets released from				
restrictions	9,794,233	(9,794,233)		
Total revenue and reclassifications	100,718,469	(1,805,686)	98,912,783	128,002,974
EXPENSES				
Program services	101,835,790	_	101,835,790	119,082,740
Fundraising	331,102	-	331,102	181,890
Management and general	9,394,147		9,394,147	8,148,138
Total expenses	111,561,038		111,561,038	127,412,768
Change in net assets	(10,842,569)	(1,805,686)	(12,648,255)	590,206
Net assets, at beginning of year	13,665,600	30,357,171	44,022,771	43,432,565
Net assets, at end of year	\$ 2,823,031	\$ 28,551,485	\$ 31,374,516	\$ 44,022,771

Statement of Functional Expenses For the Year Ended September 30, 2024 (With Summarized Financial Information for 2023)

2024									2023	
		Program Services Expenses	aı	anagement nd General Expenses	_ Fu	ndraising	То	tal Expenses	То	tal Expenses
Salaries and wages	\$	30,314,219	\$	4,462,735	\$	241,087	\$	35,018,041	\$	31,149,058
Fringe benefits		9,087,247		1,634,938		54,953		10,777,138		9,343,356
Subrecipient contract		20,759,302		-		-		20,759,302		43,896,085
Professional fees and other services		626,936		1,432,566		34,320		2,093,822		1,512,122
Contracted direct program expense		30,300,373		770,781		-		31,071,154		39,157,555
Supplies		702,930		16,055		72		719,056		391,617
Occupancy expenses		-		840,880		-		840,880		758,183
Equipment		164,565		12,295		-		176,860		133,225
Travel		49,997		5,679		69		55,745		89,322
Staff development and training expense		772,382		84,681		-		857,063		748,912
Meetings		96,443		30,616		600		127,659		70,026
Printing and materials		1,834		12,437		-		14,271		46,619
Other expenses		(59,823)		7,641		-		(52,182)		(4,160)
Depreciation and amortization		-		82,844		-		82,844		120,848
Bad debt		9,019,385				-		9,019,385		
Total expenses	\$	101,835,790	\$	9,394,147	\$	331,102	\$	111,561,038	\$	127,412,768

Statements of Cash Flows

For the Years Ended September 30, 2024 and 2023

	2024	2023		
CASH FLOW FROM OPERATING ACTIVITIES				
Change in net assets	\$ (12,648,255)	\$ 590,206		
Adjustments to reconcile change in net assets to	+ (,,)	,		
net cash provided by (used in) operating activities				
Depreciation and amortization	82,844	120,848		
Realized (gain)/loss on sales of investments	(40,918)	-		
Increase in beneficial interest in assets held by	4			
others	(50,457)	(35,546)		
Change in operating assets and liabilities	27 270 240	(0.470.000)		
Change in grants and contributions receivable Other receivable	37,276,219	(8,470,099)		
Change in contract advances	1,482,792	(764,426)		
Change in prepaid expense	(7,671)	(51,359)		
Change in other assets	79,274	-		
Change in ROU assets	547,677	(2,053,791)		
Change in accounts payable and accrued		,		
expenses	(18,730,893)	9,238,748		
Change in accrued payroll and benefits	496,074	2,334,845		
Change in ROU liabilities	(487,716)	2,116,945		
Change in other liabilities	8,273,408	(7,915,204)		
Change in deferred rent		(48,177)		
Net cash provided by (used in) operating				
activities	16,272,378	(4,937,010)		
CASH FLOW FROM INVESTING ACTIVITIES				
Purchase of investments	(11,594,554)	_		
Sale of investments	1,261,989	_		
Purchase of property and equipment	-	(416,145)		
Net cash used in investing activities	(10,332,565)	(416,145)		
Net change in cash	5,939,813	(5,353,155)		
Cash and cash equivalents, at beginning of year	13,288,090	18,641,245		
Cash and cash equivalents, at end of year	\$ 19,227,903	\$ 13,288,090		

Notes to Financial Statements Years Ended September 30, 2024 and 2023

NOTE 1 ORGANIZATION

Fund for Public Health in New York, Inc. (the Organization) addresses pressing public health needs, fosters private sector support to enhance health and healthcare, and helps to educate the public regarding the protection of individual, family, and community health. The Organization administers programs across the health spectrum, including programs focused on both chronic and communicable diseases. Its programs heighten emergency preparedness, enhance individual and healthcare sector efforts to prevent disease, and support innovation and excellence in public health and healthcare programs.

The Commissioner of the City of New York Department of Health and Mental Hygiene (DOHMH) (Commissioner) recommends 12 members of the Organization's Board of Directors (the Board) following a proposal by the Board's nominating committee and ratification by a majority of the entire Board. In addition, the Commissioner and the Executive Deputy Commissioner of the DOHMH and one member of the City of New York Board of Health, who is selected by the Commissioner, serve ex-officio as members of the Board.

The U.S. Department of Health and Human Services (DHHS) was a significant source of financial support to the Organization during the fiscal year, largely through grants from the Centers for Disease Control and Prevention. The Organization is obligated under the terms of the DHHS's grants to comply with specified conditions and program requirements set forth by the grantor agency.

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting and Financial Statement Presentation

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) using the accrual basis of accounting.

Net Assets

The Organization's net assets are classified into two categories as follows:

Without Donor Restrictions

Net assets without donor restrictions are expendable for the general operations of the Organization. Such net assets reflect the revenue and expenses associated with the principal operating activities of the Organization and are not subject to donor-imposed stipulations.

Notes to Financial Statements Years Ended September 30, 2024 and 2023

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Net Assets (continued)

With Donor Restrictions

Net assets with donor restrictions are limited by donor-imposed stipulations that either expire with the passage of time or can be fulfilled and removed by the actions of the Organization pursuant to those stipulations or include donor-imposed stipulations requiring such resources to be maintained in perpetuity and the income to be utilized for operating or other donor-restricted purposes. When a donor restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of operations and changes in net assets as net assets released from restrictions. At September 30, 2024 and 2023, net assets with donor restrictions only included purpose restrictions.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Summarized Financial Information for Fiscal 2023

The accompanying financial statements include certain prior-year summarized comparative information in total, but not by net asset classification or functional category. Such information does not include sufficient detail to constitute a presentation in conformity with U.S. GAAP. Accordingly, such information should be read in conjunction with the Organization's financial statements for the year ended September 30, 2023, from which the summarized information was derived.

Cash and Cash Equivalents

The Organization maintains its cash in bank deposit accounts that may exceed federally insured limits. The Organization has not experienced any losses in such accounts. All highly liquid investments with maturities of three months or less when purchased are considered to be cash equivalents.

Notes to Financial Statements Years Ended September 30, 2024 and 2023

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Cash and Cash Equivalents (continued)

The Organization is required by an anonymous donor to maintain a separate bank account for funds donated for the purpose of establishing an endowment. Conditions made by the donor regarding changes to the status, structure or programmatic nature of the Organization could result in the funds being returned to the donor. Therefore, the Organization has classified the gift as an asset (beneficial interest in assets held by others) and a liability. As of September 30, 2024, and 2023, the Organization held such funds totaling \$1,010,578 and \$960,121, respectively.

Investments

Investments are certificates of deposit from several banks, which do not exceed federally insured limits. Certificates of deposit are mainly rolled over when due. Maturity dates are 12 months or less. Interest rates range from 0.20% to 4.50% for 2024 and 2023, respectively. The Organization has not experienced any losses in such accounts. Fair value was \$10,373,483 and \$0 at September 30, 2024 and 2023, respectively.

Beneficial Interest in Assets Held by Others

The Organization has a beneficial interest in assets held by others, which is administered by a third party (see Note 6). The Organization measures its beneficial interest in the trust at fair value of the underlying investments, which are in money market funds (see Note 5 for more information related to the determination of fair value). The amount of the Organization's beneficial interest in assets held by others is offset by a related liability since the agreement from the donor allows for the possibility of the Organization having to return the funds held in beneficial interest. Interest income earned on the beneficial interest in assets held by others is reflected in other income in the accompanying statement of operations and changes in net assets.

Property and Equipment

Property and equipment are recorded at cost or, if donated, at the fair value at the date of donation. Depreciation is recorded on a straight-line basis over the three- to 10-year estimated useful lives of the assets. Leasehold improvements are amortized on a straight-line basis over the estimated useful life of the improvement or the term of the lease, whichever is less. The Organization capitalizes all purchases of property and equipment in excess of \$5,000.

Notes to Financial Statements Years Ended September 30, 2024 and 2023

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Property and Equipment (continued)

Certain property and equipment are acquired through funds received under Federal grant agreements. According to Federal regulations, any equipment item obtained through Federal funds is subject to a lien by the Federal government. As long as the Organization maintains its tax-exempt status, and so long as the equipment is used for its intended purpose, the Organization is not required to reimburse the Federal funding source. If the stated requirements are not met, the Organization would be obligated to the Federal government in an amount equal to the fair value of the equipment. There were no reimbursements made in 2024 or 2023.

Grants Revenue and Receivable

Grants are recognized as revenue when earned.

Expense-driven grants are recognized as revenue when the qualifying expenses have been incurred and all other grant requirements have been met.

Grants based on meeting performance measures or other deliverables are recorded as revenue as the terms or deliverables are met and accepted by the funder. For such grants, grant funds received prior to the incurrence of the qualifying expenses are recorded as revenue with donor restrictions when milestones are achieved.

At September 30, 2024 and 2023, the Organization had received grants from governmental entities in the aggregate amounts of \$8,456,894 and \$30,714,070, respectively. These grants have not been recorded in the financial statements as they have not been earned.

Contributions Revenue and Receivable

Contributions, including contributed goods and services, are recorded at fair value when received or pledged. Amounts are recorded as revenue with donor restrictions if they have donor stipulations that limit the use of the donated asset. Unconditional contributions that are expected to be collected within one year are recorded at their net realizable value. Unconditional contributions that are expected to be collected beyond one year are recorded at their fair value, using a present value technique, of the estimated future cash flows, discounted at rates adjusted for risk and applicable to the years in which the promises were received. Fair value adjustments of \$0 for both years ended September 30, 2024 and 2023, were recorded to reflect contributions receivable in excess of one year at fair value (see Note 4). Amortization of the discount is credited to contributions revenue. Conditional contributions are recognized as revenue when the conditions on which they depend have been substantially met. There were no conditional contributions received for the years ended September 30, 2024 and 2023.

Notes to Financial Statements Years Ended September 30, 2024 and 2023

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Allowance for Uncollectible Accounts

The carrying value of grants receivable and contributions receivable is reduced by an appropriate allowance for uncollectible accounts, which approximates net realizable value. The Organization determines its allowance by considering several factors, including the length of time receivables are past due, the Organization's previous loss history, the donor's current ability to pay its obligation, and the condition of the general economy and the industry as a whole. Receivables outstanding longer than the payment terms are considered past due. The Organization writes off accounts receivables when they become uncollectible, and payments subsequently received on such receivables are recorded as income in the period received.

As of September 30, 2024 and 2023, the established allowance was \$8,051,454 and \$0, respectively.

Contributed Nonfinancial Assets

As required by accounting standards, the Organization recognizes the fair value of contributed (donated) goods and services when the contributed goods and services: (a) create or enhance nonfinancial assets or (b) require specialized skills, are provided by individuals possessing those skills and would need to be purchased if not provided by donation.

Contributed services totaled \$2,537,358 and \$4,137,254 in 2024 and 2023, respectively. In addition, contributed goods totaled \$0 in both 2024 and 2023. Contributed goods and services are reflected as revenue and the corresponding program expense in the accompanying statement of operations and changes in net assets.

Expense Allocations

Expenses that are not specifically attributable to program services or management and general expenses are allocated by management based on variable allocation factors.

Program Management

Salary expenses of \$252,776 and \$368,149 were allocated to programs based on Central Office staff time spent working on the program for the fiscal years ended September 30, 2024 and 2023, respectively.

Notes to Financial Statements Years Ended September 30, 2024 and 2023

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Tax Status

The Organization was incorporated as a not-for-profit corporation under the laws of the State of New York and is exempt from income taxes under Section 501(c)(3) of the Internal Revenue Code. Therefore, there is no provision for income taxes.

Management has analyzed the tax positions taken by the Organization and concluded that as of September 30, 2024 and 2023, there were uncertain tax positions taken or expected to be taken. Accordingly, no interest or penalties related to uncertain tax positions have been accrued in the accompanying financial statements.

The Organization is no longer subject to income tax examinations by U.S. Federal, state or local tax authorities for years before 2021, which is the standard statute of limitations look-back period.

Advertising Expenses

As part of its program activity, the Organization incurred advertising expenses of \$42,319 and \$143,386 for the years ended September 30, 2024 and 2023, respectively. Advertising expenses are reflected in the statement of functional expenses under professional fees and other services. Advertising expenses incurred at the time of invoicing are direct expenses to grants and are recorded in accordance with the grant terms and grant period. Advertising expenses are not capitalized.

Reclassification

Certain accounts in the prior-year financial statements have been reclassified for comparative purposes to conform with the presentation of the current-year financial statements.

Notes to Financial Statements Years Ended September 30, 2024 and 2023

NOTE 3 LIQUIDITY AND AVAILABILITY

Financial assets available for general and programmatic expenditure, that is, without donor or other restrictions limiting their use, within one year of the statement of financial position date, comprise the following:

	September 30, 2024
Cash and cash equivalents Grants receivable Contributions receivable	\$ 19,227,903 44,284,258 702,138
Total	\$ 64,214,299

As part of its liquidity management, the Organization actively manages operating cash balances to ensure that sufficient cash is available to fund general expenditures as they come due. The Organization is typically able to generate enough operating cash from its ongoing operations to fund general expenditures, but it has procedures in place to utilize other financial assets if necessary. The Organization invests a portion of its cash in excess of daily requirements in certificates of deposit that can be converted to cash in a short period of time in the event of a projected shortfall in operating cash or unanticipated cash need.

NOTE 4 GRANTS AND CONTRIBUTIONS RECEIVABLE

Contributions Receivable

As of September 30, 2024 and 2023, contributions receivable, net, are due as follows:

	2024			2023		
Less than one year One to five years	\$	702,138 -	_	\$	906,959	
Total	\$	702,138	_	\$	906,959	

Management assessed donor risk on contributions receivable outstanding over one year. A risk premium of 0.5% was determined to be appropriate as of September 30, 2024 and 2023, considering the nature and financial integrity of the organizations included in the assessment.

The discount rate applied to contributions receivable in excess of one year consisted of the application of a current two-year Treasury bill rate at that time. Amounts due in more than one year were adjusted to fair value using present value techniques that assumed discount rates of 2.10% for both 2024 and 2023, depending on the length of discount time.

Notes to Financial Statements Years Ended September 30, 2024 and 2023

NOTE 4 GRANTS AND CONTRIBUTIONS RECEIVABLE (continued)

Grants Receivable

Grants receivable represented contractual expenses incurred and reimbursable under Federal, state and local grants at September 30, 2024 and 2023 and consisted of the following:

	2024	2023
U.S. Department of Health and Human Services		
Health Resources and Services		
Administration	\$ -	\$ 877,853
Centers for Disease Control	370,210	12,112,986
Office of Assistant Secretary for Health	922,271	-
National Institute of Food and Agriculture	1,663,292	780,377
Agency for Healthcare Research and Quality	316,338	570,157
State and City of New York Departments of		
Health	48,690,068	66,395,284
Other	373,533	618,998
Less: Allowance for uncollectible receivables	(8,051,454)	
Total	\$ 44,284,258	\$ 81,355,656

NOTE 5 FAIR VALUE MEASUREMENTS

The Organization is subject to the provisions of the authoritative guidance issued by the Financial Accounting Standards Board for fair value measurements. The authoritative guidance establishes a framework that provides a fair value hierarchy to prioritize the inputs to valuation techniques used for fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described as:

- <u>Level 1:</u> Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Organization has the ability to access.
- <u>Level 2:</u> Inputs to the valuation methodology include: (1) quoted prices for similar assets or liabilities in active markets, (2) quoted prices for identical or similar assets or liabilities in inactive markets, (3) inputs other than quoted prices that are observable for the asset or liability, and (4) inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified term, the Level 2 input must be observable for substantially the full term of the asset or liability.

Notes to Financial Statements Years Ended September 30, 2024 and 2023

NOTE 5 FAIR VALUE MEASUREMENTS (continued)

<u>Level 3:</u> Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. Changes in valuation techniques may result in transfers in or out of an assigned level within the hierarchy.

The following describes the valuation methodologies used for assets measured at fair value:

Certificates of deposit and money market accounts (including beneficial interest in assets held by others) – Valuation is derived based on the closing price reported by the investment manager.

The methods used may produce a fair value calculation that may not indicate net realizable value or reflect future fair values. Furthermore, while the Organization believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

There were no assets or liabilities measured at fair value on a nonrecurring basis as of September 30, 2024 and 2023. There were no transfers between levels of the fair value hierarchy.

The following table sets forth by level, within the fair value hierarchy, the Organization's assets at fair value as of September 30, 2024:

	 Level 1	Level 2 Lev		Level 3	Total		
Cash equivalents Certificates of deposit Beneficial interest in assets held by others	\$ 822,218 10,373,483	\$	-	\$	-	\$	822,218 10,373,483
Money market funds					1,010,578		1,010,578
Total	\$ 11,195,701	\$		\$	1,010,578	\$	12,206,279

Notes to Financial Statements Years Ended September 30, 2024 and 2023

NOTE 5 FAIR VALUE MEASUREMENTS (continued)

The following table sets forth by level, within the fair value hierarchy, the Organization's assets at fair value as of September 30, 2023:

	 Level 1	Level 2		 Level 3	Total		
Cash equivalents Beneficial interest in assets held by others	\$ 7,465,808	\$	-	\$ -	\$	7,465,808	
Money market funds				 960,121		960,121	
Total	\$ 7,465,808	\$		\$ 960,121	\$	8,425,929	

The beneficial interest in assets held by others contains no liquidity restrictions and is available for withdrawal upon written notice.

The table below sets forth a summary of changes in the fair value of the Organization's Level 3 assets for the years ended September 30, 2024 and 2023:

	2024			2023		
Balance, beginning of the year Interest income	\$	960,121 50,457	_	\$	924,575 35,546	
Balance, end of year	\$	1,010,578	_	\$	960,121	

<u>Quantitative Information About Significant Unobservable Inputs Used in Level 3</u> Fair Value Measurements

The following table represents Level 3 financial instruments, the valuation technique used to measure the fair value of the financial instrument, and the significant unobservable inputs and the ranges of values for those inputs:

Instrument	Fair Value	Principal Valuation Technique	Significant Unobservable Inputs	Ranges of Input Values
Donor-advised fund	\$1,010,578	Value as reflected in the investment	 Changes in donor stipulations 	\$0 - 1,010,578\$0 - 1,010,578
		statements from the financial institution holding the beneficial interest instruments	Possible withdrawal amountPossible withdrawal date	• October 1, 2024 and thereafter

Notes to Financial Statements Years Ended September 30, 2024 and 2023

NOTE 6 BENEFICIAL INTEREST IN ASSETS HELD BY OTHERS

The Organization received funds from a certain donor to establish an endowment fund. The funds are held and managed by FJC, a foundation of philanthropic funds, as an FJC Earmarked Fund Account, which earns interest quarterly. Under the terms of the agreement, the Organization may spend 5% of the net asset value of the fund annually for general support. The donor reserves the right to designate another Section 501(c)(3) organization to receive this endowment fund if there are changes in the status, structure, or programmatic direction of the Organization that are not satisfactory to the donor. As such, the amount of the beneficial interest is also reported as a liability (endowment advance) in the accompanying statements of financial position. The amount of the endowment advance was \$867,547 at both September 30, 2024 and 2023.

The donor has complete authority and responsibility regarding the investment of the funds. As such, these funds are not subject to any endowment investment policies of the Organization. Furthermore, there is no established fair value regarding the level of the assets to be maintained or stipulations required by the donor concerning the investment.

Notes to Financial Statements Years Ended September 30, 2024 and 2023

NOTE 7 NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions held by the Organization are summarized below, and are available for the following various program services for the years ended September 30:

Purpose Restrictions

	 2024		2023
Administration	\$ 29,250		\$ 29,250
Asthma Care	1,605,389		1,732,112
COVID-19	460,810		937,335
Early Intervention	1,731,745		1,024,399
Epidemics	-		12,750
Healthy Eating	448,057		948,062
Healthy Neighborhoods	361,065		425,566
Honoraria	8,439		35,582
Maternal Health	130,402		317,693
Mental Health	850,649		520,281
Nurse Family Partnership	4,849		4,849
Opioid	16,286		16,286
Other	35,667		35,667
NYC REACH	15,783,577		19,522,227
Quickie Lab	465,389		465,389
Racial Justice and Health Equity	2,038,170		914,134
School-Based Health	4,572,833		3,406,681
ThriveNYC	 8,907	_	8,907
Total	\$ 28,551,485	_	\$ 30,357,171

Notes to Financial Statements Years Ended September 30, 2024 and 2023

NOTE 7 NET ASSETS WITH DONOR RESTRICTIONS (continued)

Net assets released from donor restrictions because of expenses incurred satisfying the restricted purposes during the years ended September 30 were as follows:

Released from Restrictions

	2024		2023	
COVID-19	\$	126,723	\$	109,199
Early Intervention		626,524		144,060
Foodborne Disease		692,654		737,105
Healthy Eating		12,750.00		-
Healthy Neighborhoods		609,465		450,608
Hepatitis C		159,502		9,090
Opioid		27,143		13,954
Other		187,291		1,514
HIV Testing		369,632		468,536
Maternal Health		-		102,166
Mental Health		-		6,725
NYC REACH		4,100,918		4,035,988
Quickie Lab		-		261,529
Racial Justice and Health Equity		927,782		528,500
School-Based Health				2,000,729
Total	\$	7,840,385	\$	8,869,702

NOTE 8 PENSION PLAN

The Organization has a defined contribution pension plan covering substantially all full-time employees who meet certain eligibility requirements. The amount contributed to the plan is a fixed percentage of participants' compensation. Net pension expense amounted to \$1,314,326 and \$974,053 for the years ended September 30, 2024 and 2023, respectively.

Notes to Financial Statements Years Ended September 30, 2024 and 2023

NOTE 9 CONTINGENCIES

Certain grants and contracts may be subject to audit by the funding sources. Such audits might result in adjustments to reimbursements claimed by the Organization for the various programs conducted for or on behalf of the funding sources. In management's opinion, any potential adjustments resulting from such audits would not have a material effect on the accompanying financial statements.

NOTE 10 LEASE COMMITMENT

In May 2011, the Organization leased new office space in New York City. In May 2015, the Organization extended the term of the lease from July 31, 2016 to February 2024. Rent through July 2016 was charged in accordance with the original agreement and after July 2016 rent is charged in accordance with the extended agreement. On November 16, 2021, the lease was extended to June 30, 2027, and for a larger space that the Organization rented.

The Organization recognizes lease liabilities and their corresponding right-of-use assets (ROU) at the lease commencement date, and initially measures the lease liabilities and ROU assets using the present value of lease payments over the defined lease term discounted using the incremental borrowing rate or risk-free rate.

The Organization's lease has fixed rental payments that have annual rent increases as stipulated in the lease agreement. The Organization also makes separate payments to the lessor based on the lessor's real estate taxes assessed on the property, utilities as well as a portion of the common area maintenance and operations associated with the property. The Organization has elected the practical expedient not to separate lease and non-lease components for the building lease.

Notes to Financial Statements Years Ended September 30, 2024 and 2023

NOTE 10 LEASE COMMITMENT (continued)

During 2024 and 2023, the Organization recognized rent expenses associated with the lease as follows:

	 2024	2023		
Operating lease cost Fixed rent expense Variable rent expense (reduction) Short-term lease cost	\$ 609,282 49,080 -	\$	591,653 73,325 -	
Net lease cost	\$ 658,362	\$	664,978	
Lease cost - operating expenses Lease cost - depreciation Lease cost - interest	\$ 23,718 634,644 -	\$	39,930 547,678 77,370	
Net lease cost	\$ 658,362	\$	664,978	

During the year ended September 30, 2024, cash and non-cash activities associated with the Organization's lease are as follows:

	2024	2023		
Cash paid for amounts in the measurement of lease liabilities Operating cash flows from operating leases	\$ 598,400	\$	649,402	
Non-cash investing and financing activities New operating lease liabilities	\$ <u>-</u>	\$	-	
Other Information				
Remaining lease term – operating leases Discount rate – operating leases		2 year 2.92%	rs 9 months	

Notes to Financial Statements Years Ended September 30, 2024 and 2023

NOTE 10 LEASE COMMITMENT (continued)

Other Information (continued)

Future minimum annual payments are as follows:

Year Ending September 30,	Amount		
0005	Φ.	045 550	
2025	\$	615,556	
2026		627,867	
2027		477,928	
Total		1,721,351	
Less: Effects of discounting		(92,122)	
Lease liabilities recognized	\$	1,629,229	

NOTE 11 CONCENTRATION OF CREDIT/REVENUE RISKS

Cash is exposed to various risks, such as interest rate, market and credit risks. To minimize such risks, the Organization maintains its cash in various bank deposit accounts that may exceed federally insured limits. At September 30, 2024 and 2023, the Organization's cash was placed into high credit quality financial institutions and, accordingly, the Organization does not anticipate any losses with respect to these depository accounts. The Organization's mission is to provide fiscal management and support for public health programs in New York City through its partnership with the DOHMH. Therefore, all program activity is concentrated within the New York City geographic region. During the fiscal years ended 2024 and 2023, the Organization received 83% and 86%, respectively, of its Federal funding from the CDC. Such funding accounted for 20% of the Organization's total revenue. The Organization also received a significant portion of its funding from the City of New York accounted for 57% and 69% of the Organization's total revenue for fiscal years ended 2024 and 2023, respectively.

Due to the concentration of funds from Federal, New York State and New York City sources, there is a risk that the Organization would not be able to continue in its current capacity or support certain programs if this source of funding was to be lost. Management is confident that the Organization would continue to be able to perform its functions through reductions and cost-cutting measures as a result of the unique nature of its partnership with the DOHMH.

Notes to Financial Statements Years Ended September 30, 2024 and 2023

NOTE 12 PROPERTY AND EQUIPMENT

Property and equipment, net, at September 30, 2024 and 2023, consisted of the following:

	 2024	2023		
Leasehold improvements	\$ 194,094	\$	194,094	
Furniture and fixtures	472,998		472,998	
Computer software and hardware	 129,830		129,830	
Total cost	796,922		796,922	
Less: Accumulated depreciation	 579,293		496,449	
Property and equipment, net	\$ 217,629	\$	300,473	

NOTE 13 SUBSEQUENT EVENTS

The Organization evaluates events occurring after the date of the financial statements to consider whether the impact of such events needs to be reflected or disclosed in the financial statements. Such evaluation was performed through June 30, 2025, the date these financial statements were available for issuance.

SUPPLEMENTARY INFORMATION AND INDEPENDENT AUDITOR'S REPORTS

Federal Grantor/Pass Through Grantor/Program Title	Federal Assistance Listing Number	Pass-Through Entity Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
United States Department of Health and Human Services				
Centers for Disease Control and Prevention				
Cooperative Agreements for Diabetes Control Programs (6/30/2023 - 06/29/2025)	93.988	N/A	\$ 198,000	\$ 947,285
Total Cooperative Agreements for Diabetes Control Programs			198,000	947,285
Injury Prevention and Control Research and State and Community Based Programs (9/1/2023-08/31/2024)	93.136	N/A	-	218,520
Injury Prevention and Control Research and State and Community Based Programs (9/1/2024-08/31/2025)	93.136	N/A		1,587,301
Total Injury Prevention and Control Research and State and Community Based Programs				1,805,821
The National Cardiovascular Health Program (9/30/2023-9/29/2024)	93.426	N/A	40,000	777,808
Total The National Cardiovascular Health Program			40,000	777,808
COVID-19 - Activities to Support State, Tribal, Local and Territorial (STLT) Health Department Response to Public Health or Healthcare Crises (6/1/2021-8/31/2024)	93.391	N/A	1,992,324	2,846,524
Total COVID-19 - Activities to Support State, Tribal, Local and Territorial (STLT) Health				
Department Response to Public Health or Healthcare Crises			1,992,324	2,846,524
Assistance Programs for Chronic Disease Prevention and Control (09/30/2023 - 09/29/2026)	93.945	N/A		312,168
Total Assistance Programs for Chronic Disease Prevention and Control				312,168
Passed through New York City Department of Health and Mental Hygiene				
Capacity Building Assistance (CBA) for High-Impact HIV Prevention (7/1/2023-6/30/2024)	93.834	22FB012601R0X00	-	100,000
Capacity Building Assistance (CBA) for High-Impact HIV Prevention (7/1/2023-6/30/2024)	93.834	22FB012601R0X00	-	22,466
Capacity Building Assistance (CBA) for High Impact HIV Prevention (07/1/2023 - 6/30/2025)	93.834	22FB012601R0X00		518,205
Total Capacity Building Assistance for High-Impact HIV Prevention				640,671

Federal Grantor/Pass Through Grantor/Program Title	Federal Assistance Listing Number	Pass-Through Entity Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
United States Department of Health and Human Services (continued)				
Passed through New York City Department of Health and Mental Hygiene (continued)				
COVID-19 - Immunization Cooperative Agreements (7/1/2023-6/30/2025)	93.268	22FB012601R0X00	\$ 4,722,134	\$ 8,189,292
COVID-19 - Immunization Cooperative Agreements (7/1/2023-6/30/2025)	93.268	22FB012601R0X00	4,833,981	5,356,686
COVID-19 - Immunization Cooperative Agreements (7/1/2023-6/30/2025)	93.268	22FB012601R0X00	· · · · · -	226,552
COVID-19 - Immunization Cooperative Agreements (7/1/2023-5/31/2025)	93.268	22FB012601R0X00	-	2,288,272
COVID-19 - Immunization Cooperative Agreements (7/1/2023-6/30/2025)	93.268	22FB001501R0X00	-	520,348
COVID-19 - Immunization Cooperative Agreements (7/1/2024-6/30/2025)	93.268	22FB012601R0X00	-	114,098
COVID-19 - Immunization Cooperative Agreements (7/1/2023-6/20/2024)	93.268	22FB012601R0X00	-	1,326,380
COVID-19 - Immunization Cooperative Agreements (7/1/2021-6/20/2024)	93.268	22FB001501R0X00		2,474,884
Total COVID-19 - Immunization Cooperative Agreements			9,556,115	20,496,512
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2026)	93.323	22FB012501R0X00	_	50,765
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012501R0X00	_	116,892
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012501R0X00	_	1,599,429
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2024)	93.323	22FB001501R0X00	_	83,113
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2024)	93.323	22FB001501R0X00	-	119,207
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012501R0X00	-	492,757
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB001501R0X00	-	1,854,815
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2024)	93.323	22FB001501R0X00	-	309,412
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012501R0X00	-	3,273,330
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012601R0X00	-	483,944
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012601R0X00	-	472,032
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012601R0X00	-	334,287
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2024)	93.323	22FB012601R0X00	-	73,875
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012601R0X00	-	2,829,982
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012601R0X00	-	21,600
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012601R0X00	-	4,716,687
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012601R0X00	-	90,612
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012601R0X00	-	270,419
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-12/31/2024)	93.323	22FB012601R0X00	-	141,739
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-6/30/2025)	93.323	22FB012601R0X00	-	684,168
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2024)	93.323	22FB012601R0X00	-	578,354
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012601R0X00	-	2,293,553
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-7/31/2024)	93.323	22FB012601R0X00	-	119,587

Federal Grantor/Pass Through Grantor/Program Title	Federal Assistance Listing Number	Pass-Through Entity Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
United States Department of Health and Human Services (continued)				
Passed through New York City Department of Health and Mental Hygiene (continued)	00.000	005004000400000	•	Φ 0.440.000
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2024) Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323 93.323	22FB012601R0X00 22FB012601R0X00	\$ -	\$ 2,116,933 162,529
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025) Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-6/30/2025)	93.323	22FB012601R0X00	-	3,541,973
Total Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)				26,831,994
Project Grants and Cooperative Agreements for Tuberculosis Control Programs (7/1/2024-6/30/2025)	93.116	22FB001501R0X00	-	428,575
Project Grants and Cooperative Agreements for Tuberculosis Control Programs (7/1/2022-6/30/2025)	93.116	22FB001501R0X00		43,312
Total Project Grants and Cooperative Agreements for Tuberculosis Control Programs				471,887
Preventing Maternal Deaths: Supporting Maternal Mortality Review Committees (7/1/2022-6/30/2025)	93.478	22FB012601R0X00		203,328
Total Preventing Maternal Deaths: Supporting Maternal Mortality Review Committees				203,328
Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Virus Syndrome (AIDS) Surveillance (7/1/2023-6/30/2025)	93.944	22FB012601R0X00	-	235,240
Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Virus Syndrome (AIDS) Surveillance (8/1/2022-6/30/2025)	93.944	22FB012601R0X00		41,379
Total Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Virus Syndrome (AIDS) Surveillance)			276,619
HIV Prevention Activities Health Department Based (7/1/2023-6/30/2025)	93.94	22FB012601R0X00	-	904,000
HIV Prevention Activities Health Department Based (7/1/2022-6/30/2025)	93.94	22FB012601R0X00		4,883
Total HIV Prevention Activities Health Department Based				908,883
Office of the Assistant Secretary for Health				
Teenage Pregnancy Prevention Program (7/1/2022-6/30/2024)	93.297	N/A	-	24,229
Teenage Pregnancy Prevention Program (7/1/2023-6/30/2024)	93.297	N/A		1,539,347
Total Teenage Pregnancy Prevention Program				1,563,576
Passed through New York City Department of Health and Mental Hygiene	00.407	0050040004001/00	2045::	750.401
COVID-19 - Community Programs to Improve Minority Health (7/1/2023-6/30/2025) COVID-19 - Community Programs to Improve Minority Health (7/1/2022-6/30/2025)	93.137 93.137	22FB012601R0X00 22FB012601R0X00	624,544	758,104 127,523
Total Community Programs to Improve Minority Health	30.13 <i>1</i>	221-0012001R0A00	624,544	885,627
, ,			· · · · · · · · · · · · · · · · · · ·	

Federal Grantor/Pass Through Grantor/Program Title	Federal Assistance Listing Number	Pass-Through Entity Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
United States Department of Health and Human Services (continued) Health Resources and Services Administration				
Healthy Start Initiative (4/1/2019-4/30/2024)	93.926	N/A	\$ 132,912	\$ 920,849
Total Healthy Start Initiative			132,912	920,849
Passed through New York City Department of Health and Mental Hygiene Ending the HIV Epidemic: A Plan for America - Ryan White HIV/AIDS Program Parts A and B	93.686	22FB012601R0X00	-	394,271
Total Ending the HIV Epidemic: A Plan for America - Ryan White HIV/AIDS Program Parts A and B				394,271
HIV Emergency Relief Project Grants (7/1/2023-6/30/2025)	93.914	22FB012601R0X00		1,932,465
Total HIV Emergency Relief Project Grants				1,932,465
Substance Abuse and Mental Health Services Administration Passed through New York City Department of Health and Mental Hygiene Comprehensive Community Mental Health Services for Children with Serious Emotional Disturbances (SED) (7/1/2024-6/30/2025)	93.104	22FB012601R0X00	-	195,558
Comprehensive Community Mental Health Services for Children with Serious Emotional Disturbances (SED) (7/1/2024-6/30/2025)	93.104	22FB012601R0X00		22,668
Total Comprehensive Community Mental Health Services for Children with Serious Emotional Disturbances (SED)				218,226
Administration for Children and Families Passed through New York City Department of Health and Mental Hygiene 477 Cluster				
Child Care and Development Block Grant (7/1/2023 to 6/30/2025)	93.575	22FB001501R0X00	-	387,431
Child Care and Development Block Grant (7/1/2022 to 6/30/2024)	93.575	22FB001501R0X00		26,947
Total Child Care and Development Block Grant				414,378
Total 477 Cluster				414,378

Federal Grantor/Pass Through Grantor/Program Title	Federal Assistance Listing Number	Pass-Through Entity Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
Administration for Community Living (HHS-ACL) Passed through National Council on Aging COVID-19 -Special Programs for the Aging, Title IV, and Title II, Discretionary Projects (5/17/2023-4/30/2024)	93.048	N/A	\$ 394,080	\$ 502,974
Total COVID-19 -Special Programs for the Aging, Title IV, and Title II, Discretionary Projects			394,080	502,974
Research and Development Cluster Centers for Disease Control and Prevention Environmental Public Health and Emergency Response (09/30/20-09/29/25)	93.070	N/A		193,673
Total Environmental Public Health and Emergency Response				193,673
Agency for Healthcare Research and Quality Research on Healthcare Costs, Quality and Outcomes (9/30/2020-09/29/2024) Total Research on Healthcare Costs, Quality and Outcomes	93.226	N/A		110,276 110,276
National Institutes of Health Passed through Columbia University Nursing Research (09/21/2023 - 06/30/2028) Total Nursing Research	93.361	01NR021108		36,262 36,262
Passed through New York University COVID-19 - Nursing Research (07/01/2020-06/30/2024) Total COVID-19 - Nursing Research	93.361	21-A0-00-1007163		<u>27,403</u> <u>27,403</u>
Passed through New York City Department of Health and Mental Hygiene Diabetes, Digestive, and Kidney Diseases Extramural Research (7/1/2023-6/30/2025) Diabetes, Digestive, and Kidney Diseases Extramural Research (7/1/2021-6/30/2025) Total Diabetes, Digestive, and Kidney Diseases Extramural Research	93.847 93.847	22FB012601R0X00 22FB012601R0X00	· ·	101,426 14,142 115,568

Federal Grantor/Pass Through Grantor/Program Title	Federal Assistance Listing Number	Pass-Through Entity Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
National Institutes of Health (continued) Passed through New York City Department of Health and Mental Hygiene				
Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders (7/1/2022-6/30/2025) Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep	93.840	22FB012601R0X00	\$ -	\$ 194,948
Disorders (7/1/2022-6/30/2025)	93.840	22FB012601R0X00		36,365
Total Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders			<u> </u>	231,313
Total Research and Development Cluster				714,495
Total United States Department of Health and Human Services			12,937,975	64,066,361
United States Department of Housing and Urban Development Assistant Secretary for Community Planning and Development Passed through New York City Department of Health and Mental Hygiene Housing Opportunities for Persons with AIDS (7/1/2023-6/30/2025) Housing Opportunities for Persons with AIDS (7/1/2022-8/31/2025)	14.241 14.241	22FB012601R0X00 22FB012601R0X00	<u> </u>	479,150 21,529
Total Housing Opportunities for Persons with AIDS				500,679
Total United States Department of Housing and Urban Development				500,679
United States Department of Agriculture National Institute of Food and Agriculture				
COVID-19 - Gus Schumacher Nutrition Incentive Program (8/1/2021-7/31/2025)	10.331	N/A	-	454,183
Gus Schumacher Nutrition Incentive Program (9/1/2020-8/31/2024) Gus Schumacher Nutrition Incentive Program (9/15/2023 - 9/14/2026)	10.331 10.331	N/A N/A	<u> </u>	1,821,113 618_
Total Gus Schumacher Nutrition Incentive Program				2,275,914

Federal Grantor/Pass Through Grantor/Program Title	Federal Assistance Listing Number	Pass-Through Entity Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
Food and Nutrition Service Passed through New York City Department of Health and Mental Hygiene Supplemental Nutrition Assistance Program Cluster State Administrative Matching Grants for the Supplemental Nutrition Assistance Program (10/1/2022-9/30/2028) State Administrative Matching Grants for the Supplemental Nutrition Assistance Program (10/1/2022-9/30/2028)	10.561 10.561	22FB012601R0X00 22FB012601R0X00	\$ - 	\$ 844,964 17,720_
Total State Administrative Matching Grants for the Supplemental Nutrition Assistance Program				862,684
Total Supplemental Nutrition Assistance Program Cluster				862,684
Total United States Department of Agriculture				3,138,598
Total Federal Awards Passed Through to Subrecipients			\$ 12,937,975	
Total Federal Awards				\$ 67,705,638

Notes to Schedule of Expenditures of Federal Awards For the Year Ended September 30, 2024

NOTE 1 BASIS OF PRESENTATION

The accompanying schedule of expenditures of federal awards (the Schedule) includes the Federal grant and contract activity of the Organization under the programs of the federal government for the year ended September 30, 2024. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations (CFR) Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (the Uniform Guidance). Because the Schedule presents only a selected portion of the operations of the Organization, it is not intended to, and it does not, present the financial position, changes in net assets, or cash flows of the Organization.

NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES

Expenditures reported on the Schedule are on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. The Organization has elected not to use the 10% de minimis indirect cost rate allowed under the Uniform Guidance.

NOTE 3 SUBRECIPIENTS

The Organization provided Federal awards to subrecipients, as follows:

Program Title	Federal Assistance Listing Number	Subrecipient Name	Amount Provided to Subrecipient	
Cooperative Agreements for Diabetes Control Programs (6/30/2023 - 06/29/2025)	93.988	APC Community Services Episcopal Health Services Inc. Health People Inc. Korean Community Services of Metropolitan New York Inc. RiseBoro Community Partnership, Inc. Subtotal	\$ 60,000 6,000 12,000 60,000 60,000 198,000	
The National Cardiovascular Health Program (9/30/2023-9/29/2024)	93.426	APC Community Services Lasante Health Center Inc. Essen Medical Associates PC	30,000 5,000 5,000	
COVID-19 - Activities to Support State, Tribal, Local and Territorial (STLT) Health Department Response to Public Health or Healthcare Crises (6/1/2021-8/31/2024)	93.391	Subtotal Boro Park Jewish Community Council Inc. Brooklyn Bureau of Community Service dba Brooklyn Community Services Fund for the City of New York Inc. India Home Inc. Jewish Community Council of Greater Coney Island, Inc. Mexican Coalition for the Empowerment of Youth and Families, Inc. Phipps Neighborhoods, Inc. Public Health Solutions The Central Family Life Center Inc. The Haitian Americans United for Progress, Inc.	40,000 240,888 262,478 230,037 248,332 146,110 197,357 240,905 218,007 127,698 80,512	
		Subtotal	1,992,324	

FUND FOR PUBLIC HEALTH IN NEW YORK, INC.Notes to Schedule of Expenditures of Federal Awards *(continued)*For the Year Ended September 30, 2024

SUBRECIPIENTS (continued) NOTE 3

Program Title	Federal Assistance Listing Number	Subrecipient Name	
COVID-19 - Immunization Cooperative			
Agreements (7/1/2023-6/30/2025)	93.268	Bangladeshi American Community Development and Youth Services	\$ 169,919
		Brooklyn Bureau of Community Service dba Brooklyn Community Services	294,603
		CABS Home Attendant Services, Inc.	817,184
		Chhaya Community Development Corporation	170,611
		Community Health Action of Staten Island, Inc.	1,265,175
		Fund for the City of New York Inc.	233,128
		Harlem Congregations	(532,578
		Korean Community Services of Metropolitan New York Inc.	150,849
		Life Church	62,180
		Mosholu-Montefiore Community Center, Inc.	59,009
		Phoenix Houses of Long Island, Inc.	209,65
		Project Hospitality Inc.	181,285
		Project New Yorker Corporation	339,20
		Relume Foundation Inc.	228,638
		Somos Healthcare Providers, Inc.	311,513
		The Central Family Life Center Inc.	164,717
		Transnational Villages Network - Red de Pueblos Transnacionales	174,36
		United Sikhs in Service of America	169,924
		Word of Life International Inc.	252,75
		Beacon Christian Community Health Center Brownsville Community Develop Corp dba Brownsville Multi Service Family Health C	177,50 164,35
		Charles B Wang Community Health Center Inc	356,03
		East Harlem Council For Human Services, Inc.	300,15
		Episcopal Health Services Inc.	279,60
		Essen Medical Associates PC	210,78
		Essen Medical Urgicare, PLLC	122,91
		First Medicare Inc.	271,65
		HASC Diagnostic and Treatment Center, Inc. dba Rambam Family Health	273,358
		Hudson River HealthCare Inc. dba Sun River Health	291,148
		Jamaica Hospital Medical Center	313,69
		Lasante Health Center Inc.	326,038
		L'Refuah Medical & Rehabilitation Center Inc Dba Ezra Medical Center Inc.	286,352
		Morris Heights Health Center Inc.	276,45
		Premium Health, Inc.	295,690
		Union Community Health Center	310,42
		Urban Health Plan Inc.	266,643
		William Ryan Community Health Centers	311,157
		Subtotal	9,556,115
	93.137	Endangered Language Alliance	66.382
		Rebecca G. Scott dba Sustainable Snacks LLC	64,275
		RiseBoro Community Partnership, Inc.	212,247
		Samuel Field YM & YWHA, Inc.	281,640
		Subtotal	624,544
	93.926	Brookdale University Hospital & Medical Center	56,303
		Brooklyn Perinatal Network Inc.	13,832
		Caribbean Womens Health Association Inc.	29,122
		The Brookdale Hospital Medical Center	33,655
		Subtotal	132,912
	93.048	Fund for the City of New York Inc.	118,145
		RiseBoro Community Partnership, Inc.	196,845
		Rockaway Waterfront Alliance Inc	79,090
		Subtotal	394,080
		Grand total	\$ 12,937,975

Notes to Schedule of Expenditures of Federal Awards *(continued)* For the Year Ended September 30, 2024

NOTE 4 RECONCILIATION OF SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS TO AUDITED FINANCIAL STATEMENTS

Total expenditures, as reflected in the Schedule, vary from the amount reported in the statement of operations and changes in net assets as Federal revenue due to the inclusion of several pass-through contracts as well as Federal expenditures that were paid for via program revenue or other matching funds. The revenue related to these reconciling items is reflected in other grants and contributions revenue in the accompanying statement of operations and changes in net assets. The reconciling items are listed below:

Total expenses per SEFA schedule			\$ 67,705,638
	Federal Assistance	Pass-Through	
Federal Grantor/Pass Through Grantor/Program Title	Listing Number	Grant #	Amount
Passed through New York City Department of Health and Mental Hygiene			
Capacity Building Assistance (CBA) for High-Impact HIV Prevention (7/1/2023-6/30/2024)	93.834	22FB012601R0X00	\$ 100,000
Capacity Building Assistance (CBA) for High-Impact HIV Prevention (7/1/2023-6/30/2024)	93.834	22FB012601R0X00	22,466
Capacity Building Assistance (CBA) for High Impact HIV Prevention (07/1/2023 - 6/30/2025)	93.834	22FB012601R0X00	518,205
Total Capacity Building Assistance for High-Impact HIV Prevention			640,671
COVID-19 - Immunization Cooperative Agreements (7/1/2023-6/30/2025)	93.268	22FB012601R0X00	8,189,292
COVID-19 - Immunization Cooperative Agreements (7/1/2023-6/30/2025)	93.268	22FB012601R0X00	5,356,686
COVID-19 - Immunization Cooperative Agreements (7/1/2023-6/30/2025)	93.268	22FB012601R0X00	226,552
COVID-19 - Immunization Cooperative Agreements (7/1/2023-5/31/2025) COVID-19 - Immunization Cooperative Agreements (7/1/2023-6/30/2025)	93.268 93.268	22FB012601R0X00 22FB001501R0X00	2,288,272 520,348
COVID-19 - Immunization Cooperative Agreements (7/1/2023-6/30/2025) COVID-19 - Immunization Cooperative Agreements (7/1/2024-6/30/2025)	93.268	22FB012601R0X00	114.098
COVID-19 - Immunization Cooperative Agreements (7/1/2023-6/20/2024)	93.268	22FB012601R0X00	1,326,380
COVID-19 - Immunization Cooperative Agreements (7/1/2021-6/20/2024)	93.268	22FB001501R0X00	2,474,884
Total COVID-19 - Immunization Cooperative Agreements			20,496,512
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2026)	93.323	22FB012501R0X00	50.765
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012501R0X00	116,892
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012501R0X00	1,599,429
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2024)	93.323	22FB001501R0X00	83,113
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2024)	93.323	22FB001501R0X00	119,207
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012501R0X00	492,757
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB001501R0X00	1,854,815
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2021-6/30/2024)	93.323	22FB001501R0X00	309,412
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025) COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323 93.323	22FB012501R0X00 22FB012601R0X00	3,273,330 483,944
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012601R0X00	472,032
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012601R0X00	334.287
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2024)	93.323	22FB012601R0X00	73,875
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012601R0X00	2,829,982
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012601R0X00	21,600
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012601R0X00	4,716,687
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012601R0X00	90,612
COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025) COVID-19 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-12/31/2024)	93.323 93.323	22FB012601R0X00 22FB012601R0X00	270,419 141.739
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-6/30/2025)	93.323	22FB012601R0X00	684.168
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2024)	93.323	22FB012601R0X00	578,354
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012601R0X00	2,293,553
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-7/31/2024)	93.323	22FB012601R0X00	119,587
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2024)	93.323	22FB012601R0X00	2,116,933
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2023-6/30/2025)	93.323	22FB012601R0X00	162,529
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) (7/1/2022-6/30/2025)	93.323	22FB012601R0X00	3,541,973
Total Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)			26,831,994
Project Grants and Cooperative Agreements for Tuberculosis Control Programs (7/1/2024-6/30/2025)	93.116	22FB001501R0X00	428,575
Project Grants and Cooperative Agreements for Tuberculosis Control Programs (7/1/2022-6/30/2025)	93.116	22FB001501R0X00	43,312
Total Project Grants and Cooperative Agreements for Tuberculosis Control Programs			471,887
Preventing Maternal Deaths: Supporting Maternal Mortality Review Committees (7/1/2022-6/30/2025)	93.478	22FB012601R0X00	203,328
Total Preventing Maternal Deaths: Supporting Maternal Mortality Review Committees			203,328
Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Virus Syndrome (AIDS) Surveillance (7/1/2023-6/30/2025)	93.944	22FB012601R0X00	235,240
Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Virus Syndrome (AIDS) Surveillance (8/1/2022-6/30/2025)	93.944	22FB012601R0X00	41,379
Total Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Virus Syndrome (AIDS) Surveillance			276,619
HIV Prevention Activities Health Department Based (7/1/2023-6/30/2025) HIV Prevention Activities Health Department Based (7/1/2022-6/30/2025)	93.940 93.940	22FB012601R0X00 22FB012601R0X00	904,000 4,883
Total HIV Prevention Activities Health Department Based	30.340	221 00 1200 1100000	908,883
Passed through New York City Department of Health and Mental Hygiene			
COVID-19 - Community Programs to Improve Minority Health (7/1/2023-6/30/2025)	93.137	22FB012601R0X00	758.104
COVID-19 - Community Programs to Improve Minority Health (7/1/2022-6/30/2025)	93.137	22FB012601R0X00	127,523
Total Community Programs to Improve Minority Health			885,627
rotal commany registrate improve minority registration			555,021

Notes to Schedule of Expenditures of Federal Awards *(continued)* For the Year Ended September 30, 2024

NOTE 4 RECONCILIATION OF SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS TO AUDITED FINANCIAL STATEMENTS (continued)

Federal Grantor/Pass Through Grantor/Program Title	Federal Assistance Listing Number	Pass-Through Grant #	Amount
Passed through New York City Department of Health and Mental Hygiene			
Ending the HIV Epidemic: A Plan for America - Ryan White HIV/AIDS Program Parts A and B Total Ending the HIV Epidemic: A Plan for America - Ryan White HIV/AIDS Program Parts A and B	93.686	22FB012601R0X00	\$ 394,271 394,271
HIV Emergency Relief Project Grants (7/1/2023-6/30/2025)	93.914	22FB012601R0X00	1,932,465
Total HIV Emergency Relief Project Grants			1,932,465
Substance Abuse and Mental Health Services Administration Passed through New York City Department of Health and Mental Hygiene Comprehensive Community Mental Health Services for Children with Serious Emotional Disturbances (SED) (7/1/2024-6/30/2025) Comprehensive Community Mental Health Services for Children with Serious Emotional Disturbances (SED) (7/1/2024-6/30/2025)	93.104 93.104	22FB012601R0X00 22FB012601R0X00	195,558 22,668
Total Comprehensive Community Mental Health Services for Children with Serious Emotional Disturbances (SED)			218,226
Administration for Children and Families Passed through New York City Department of Health and Mental Hygiene Child Care and Development Block Grant (7/1/2023 to 6/30/2025) Child Care and Development Block Grant (7/1/2022 to 6/30/2024) Total Child Care and Development Block Grant	93.575 93.575	22FB001501R0X00 22FB001501R0X00	387,431 26,947 414,378
•			414,370
Administration for Community Living (HHS-ACL) Passed through National Council on Aging COVID-19 -Special Programs for the Aging, Title IV, and Title II, Discretionary Projects (5/17/2023-4/30/2024)	93.048	N/A	502,974
Total COVID-19 -Special Programs for the Aging, Title IV, and Title II, Discretionary Projects			502,974
National Institutes of Health Passed through Columbia University Nursing Research (09/21/2/023 - 06/30/2028)	93.361	01NR021108	36,262
Total Nursing Research			36,262
Passed through New York University COVID-19 - Nursing Research (07/01/2020-06/30/2024)	93.361	21-A0-00-1007163	27,403
Total COVID-19 - Nursing Research			27,403
Passed through New York City Department of Health and Mental Hygiene Diabetes, Digestive, and Kidney Diseases Extramural Research (7/1/2024-8/30/2025) Diabetes, Digestive, and Kidney Diseases Extramural Research (7/1/2021-8/30/2025)	93.847 93.847	22FB012601R0X00 22FB012601R0X00	101,426 14,142
Total Diabetes, Digestive, and Kidney Diseases Extramural Research			115,568
Passed through New York City Department of Health and Mental Hygiene Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders (7/1/2022-6/30/2025) Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders (7/1/2022-6/30/2025)	93.840 93.840	22FB012601R0X00 22FB012601R0X00	194,948 36,365
Total Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders			231,313
Total Research and Development Cluster			410,546
Total United States Department of Health and Human Services			54,588,381
United States Department of Housing and Urban Development Assistant Secretary for Community Planning and Development Passed through New York City Department of Health and Mental Hygiene Housing Opportunities for Persons with AIDS (7/1/2023-6/30/2025) Housing Opportunities for Persons with AIDS (7/1/2023-6/30/2025)	14.241 14.241	22FB012601R0X00 22FB012601R0X00	479,150 21,529
Total Housing Opportunities for Persons with AIDS			500,679
Total United States Department of Housing and Urban Development			500,679
Food and Nutrition Service Passed through New York City Department of Health and Mental Hygiene State Administrative Matching Grants for the Supplemental Nutrition Assistance Program (10/1/2022-9/30/2028) State Administrative Matching Grants for the Supplemental Nutrition Assistance Program (10/1/2022-9/30/2028)	10.561 10.561	22FB012601R0X00 22FB012601R0X00	844,964 17,720
Total Food and Nutrition Service			862,684
Total United States Department of Agriculture			862,684
Subtotal Passthrough adjustments			55,951,744
Add: Other adjustments Prior year/Adjustments			(187,792)
Subtotal other adjustments			(187,792)
SEFA federal revenue adjusted Federal revenue financial statement			11,566,102 \$ 11,566,102



INDEPENDENT AUDITOR'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS

To Management and the Board of Directors Fund for Public Health in New York. Inc.

We have audited in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of Fund for Public Health in New York, Inc. (the Organization), which comprise the statement of financial position as of September 30, 2024, the related statements of operations and changes in net assets, functional expenses and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated June 30, 2025.

Report on Internal Control over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Organization's internal control over financial reporting (internal control) as a basis for designing procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, we do not express an opinion on the effectiveness of the Organization's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that were not identified. Given these limitations, during our audit we did not identify any deficiencies in internal control over financial reporting that we consider to be material weaknesses. We did identify a certain deficiency in internal control, described in the accompanying schedule of findings and questioned costs as item 2024-001 that we consider to be a significant deficiency.

80 Pine Street New York, NY 10005 **T** +1 212 709 4500 **F** +1 212 709 4680

37 mitchelltitus.com



Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Organization's financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit and, accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

The Organization's Response to Findings

Mitchell: Titus, LLP

The Organization's response to the finding identified in our audit is described in the accompanying schedule of findings and questioned costs. The Organization's response was not subjected to the auditing procedures applied in the audit of the financial statements and, accordingly, we express no opinion on it.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

June 30, 2025



INDEPENDENT AUDITOR'S REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM AND REPORT ON INTERNAL CONTROL OVER COMPLIANCE IN ACCORDANCE WITH THE UNIFORM GUIDANCE

To Management and the Board of Directors Fund for Public Health in New York, Inc.

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Fund for Public Health in New York, Inc.'s (the Organization) compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Organization's major federal programs for the year ended September 30, 2024. The Organization's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Organization complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended September 30, 2024.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (the Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Organization and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Organization's compliance with the compliance requirements referred to above.



Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Organization's federal programs.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Organization's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Organization's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Organization's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Organization's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.



Report on Internal Control over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit, we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Mitchell: Titus, LLP

June 30, 2025

Schedule of Findings and Questioned Costs For the Year Ended September 30, 2024

SECTION I—SUMMARY OF AUDITOR'S RESULTS

Financial Statements Type of auditor's report issued (unmodified, qualified, adverse, or disclaimer): Unmodified Internal control over financial reporting: _____ Yes X No Material weakness(es) identified? Significant deficiency(ies) identified? X Yes None Reported Noncompliance material to financial _____ Yes <u>X</u> No statements noted? **Federal Awards** Internal control over major federal programs: Yes X No Material weakness(es) identified? Significant deficiency(ies) identified? Yes X None Reported Type of auditor's report issued on compliance for major federal programs (unmodified, qualified, adverse, or disclaimer): Unmodified Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)? Yes X No Identification of major federal programs: Federal Assistance Listing Number(s) Name of Federal Program or Cluster 10.331 COVID-19 - Gus Schumacher Nutrition Incentive Program

COVID-19 - Epidemiology and Laboratory

Capacity for Infectious Diseases

93.323

Schedule of Findings and Questioned Costs *(continued)* For the Year Ended September 30, 2024

SECTION I—SUMMARY OF AUDITOR'S RESULTS (continued)

Dollar threshold used to distinguish between type A and type B programs:	\$2,031,169			
Auditee qualified as low-risk auditee?	Χ	Yes	No	

SECTION II—FINANCIAL STATEMENT FINDINGS

Finding 2024-001

Inadequate Controls over Financial Reporting

Criteria

U.S. GAAP requires management to establish and maintain a system of internal controls, and to ensure that financial information is accurately recorded and properly reported in the Organization's financial system. This includes the design, implementation, and maintenance of internal controls relevant to the preparation and fair presentation of financial statements that are free from material misstatements whether due to fraud or error.

Condition and Context

The Organization's system of internal controls in place over accounts receivable and more broadly over general ledger maintenance appears inadequate to ensure timely, complete, and accurate reconciliation are performed.

During our testing of accounts receivable, the Organization brought to our attention that there was a discrepancy between the amounts noted in the general ledger and subledger of accounts receivable, which amounted to \$5.9 million. In addition, during the Organization's investigation, an additional \$2.13 million was written-off once it was determined to be uncollectible. Based on these facts, management has recorded an allowance for bad debt of \$8 million, which is calculated at 18% of the Organization's largest receivable. Further inquiries indicated that these differences occurred during the migration of the Organization's accounting system, as well as significant staffing changes that prevented periodic reconciliations from being timely performed, which would have helped to prevent, detect and correct errors noted during the year. Consequently, adjustments were proposed and recorded in the financial statements to correct these misstatements at year end.

Effect

The year-end financial statements of the Organization would have been misstated without recording these client-proposed and audit adjustments. Additionally, lack of timely reconciliation of significant accounts, timely billings to grantor agency(ies), and maintaining supporting documentation could result in future misstatements.

Schedule of Findings and Questioned Costs *(continued)* For the Year Ended September 30, 2024

SECTION II—FINANCIAL STATEMENT FINDINGS (continued)

Finding 2024–001 (continued)

Inadequate Controls over Financial Reporting (continued)

Cause

Based on our discussions with management, the discrepancies occurred during the migration to a modified version of the existing accounting system. This included re-coding general ledger accounts, restructuring workflows, and migrating data from the legacy system. The initial data transfer was unsuccessful, and a second attempt was required to complete the migration. These disruptions and delays experienced during the migration, as well as inadequate staffing, significantly resulted in inefficiencies and ineffective internal controls over the accounting system required to properly present the financial statements in accordance with U.S. GAAP.

Recommendations

We recommend that the Organization enhance its monthly and annual reconciliations of accounts receivable subledger against grantor(s) payments, and also implement procedures for the financial reporting and closing process to ensure all general ledger accounts are accurate, reconciled against the subledgers, and reviewed in a timely manner.

Views of Responsible Officials:

Management agrees with the recommendation. The Organization's corrective action plan is on page 46.

SECTION III—FEDERAL AWARD FINDINGS AND QUESTIONED COSTS

No matters were reported.

SECTION IV—PRIOR-YEAR AUDIT FINDINGS

No matters were reported.



FPHNY FY24 Audit Responses

SECTION II—FINANCIAL STATEMENT FINDINGS

Audit Finding Reference: 2024-001 Inadequate Controls over Financial Reporting

Planned Corrective Action: We will develop a procedure, monthly close, and reconciliations to ensure proper recording of receivables and the overall general ledger maintenance.

Person Responsible for Corrective Action: The corrective action plan will be the responsibility of Jose Garzon, the Chief Financial Officer along with the assistance of the Directors of Finance and Controller.

Anticipated Completion Date: We will have the corrective action plan in place by the end of fiscal year 2025 4th fiscal quarter.

